111 related articles for article (PubMed ID: 12569289)
1. Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial.
Neuber K; Reinhold U; Deutschmann A; Pföhler C; Mohr P; Pichlmeier U; Baumgart J; Hauschild A
Melanoma Res; 2003 Feb; 13(1):81-5. PubMed ID: 12569289
[TBL] [Abstract][Full Text] [Related]
2. Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials.
Neuber K
Recent Results Cancer Res; 2003; 161():159-79. PubMed ID: 12528807
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
Atzpodien J; Terfloth K; Fluck M; Reitz M
Br J Cancer; 2007 Nov; 97(10):1329-32. PubMed ID: 17971774
[TBL] [Abstract][Full Text] [Related]
4. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
Spieth K; Kaufmann R; Gille J
Cancer Chemother Pharmacol; 2003 Nov; 52(5):377-82. PubMed ID: 12879280
[TBL] [Abstract][Full Text] [Related]
5. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo.
Neuber K; tom Dieck A; Blödorn-Schlicht N; Itschert G; Karnbach C
Melanoma Res; 1999 Apr; 9(2):125-32. PubMed ID: 10380934
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma.
Schmidt-Hieber M; Schmittel A; Thiel E; Keilholz U
Melanoma Res; 2004 Dec; 14(6):439-42. PubMed ID: 15577312
[TBL] [Abstract][Full Text] [Related]
7. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
8. Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity.
Meden H; Wittkop Y; Kuhn W
Anticancer Res; 1997; 17(3C):2221-3. PubMed ID: 9216692
[TBL] [Abstract][Full Text] [Related]
9. Treosulfan chemotherapy for recurrent malignant glioma.
Schmidt F; Wick W; Herrlinger U; Dichgans J; Weller M
J Neurooncol; 2000 Sep; 49(3):231-4. PubMed ID: 11212902
[TBL] [Abstract][Full Text] [Related]
10. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
11. Treosulfan in the treatment of metastatic renal cell carcinoma.
Rigos D; Wechsel HW; Bichler KH
Anticancer Res; 1999; 19(2C):1549-52. PubMed ID: 10365143
[TBL] [Abstract][Full Text] [Related]
12. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma.
Schmittel A; Scheulen ME; Bechrakis NE; Strumberg D; Baumgart J; Bornfeld N; Foerster MH; Thiel E; Keilholz U
Melanoma Res; 2005 Jun; 15(3):205-7. PubMed ID: 15917703
[TBL] [Abstract][Full Text] [Related]
14. Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
Atzpodien J; Terfloth K; Fluck M; Reitz M
Am J Clin Oncol; 2011 Feb; 34(1):2-5. PubMed ID: 20042970
[TBL] [Abstract][Full Text] [Related]
15. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
O'Neill PA; Butt M; Eswar CV; Gillis P; Marshall E
Melanoma Res; 2006 Jun; 16(3):245-8. PubMed ID: 16718271
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
Atzpodien J; Terfloth K; Fluck M; Reitz M
Cancer Chemother Pharmacol; 2008 Sep; 62(4):685-8. PubMed ID: 18084763
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
18. Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study.
Chekerov R; Kaltenecker G; Reichert D; Göhler T; Klare P; Oskay-Özcelik G; Sauer U; Wischnik A; Vehling-Kaiser U; Becker M; Hutzschenreuter U; Ammon A; Heidrich-Lorsbach E; Sehouli J
Anticancer Res; 2015 Dec; 35(12):6869-75. PubMed ID: 26637909
[TBL] [Abstract][Full Text] [Related]
19. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
[TBL] [Abstract][Full Text] [Related]
20. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Chapman PB; Einhorn LH; Meyers ML; Saxman S; Destro AN; Panageas KS; Begg CB; Agarwala SS; Schuchter LM; Ernstoff MS; Houghton AN; Kirkwood JM
J Clin Oncol; 1999 Sep; 17(9):2745-51. PubMed ID: 10561349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]